Results 41 to 50 of about 527 (122)

Evaluation of Percutaneous Intramyocardial Septal Pulsed Field Ablation in a Rabbit Model: Safety, Efficacy, and Feasibility

Journal of Interventional Cardiology, Volume 2026, Issue 1, 2026.
Background Percutaneous intramyocardial (PIM) septal pulsed field ablation (SPFA) represents an innovative technique for the management of hypertrophic obstructive cardiomyopathy. However, the paucity of pertinent animal models has impeded comprehensive investigation. This study aimed to assess the safety, efficacy, and feasibility of PIM‐SPFA, as well
Xing-an Zhao, Hua-lei Dai, Si-ming Tao, Yi-jian Zhang, Ji Jia, Li-juan Song, Man Yang, Yun-na Ge, Xi-ya Wang, Juan Qing, Piotr Musialek   +10 more
wiley   +1 more source

Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis

American Heart Journal Plus
Background: Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac ...
Muhammad Nabeel Saddique, Hamza Irfan, Saad Ashraf, Maria Qadri, Hammad Javaid, Sana Iftikhar, Muhammad Zain ul Haq, Laveeza Fatima, Qasim Mehmood, Anurag Jha, Saad Masood, Muhammad Safiullah, Muhammad Imaz Bhatti, Sheena Shamoon, Javed Iqbal   +14 more
doaj   +1 more source

Yield of Genetic Testing in Pediatric Cardiomyopathies: Implications for Novel Therapeutic Options

Molecular Genetics &Genomic Medicine, Volume 13, Issue 7, July 2025.
Pediatric cardiomyopathies are rare, heterogeneous, and challenging conditions, often with a genetic etiology. We estimated the yield of genetic testing in a pediatric cohort with cardiomyopathies and evaluated the potential candidacy to current or emerging treatments based on genetic results. Over one‐third had a conclusive genetic test, including 25%
Adelaide Ballerini, Francesca Girolami, Alessia Gozzini, Silvia Passantino, Mattia Zampieri, Alberto Marchi, Alessia Tomberli, Giovanni B. Calabri, Gaia Spaziani, Giulio Porcedda, Elena Bennati, Silvia Favilli, Iacopo Olivotto   +12 more
wiley   +1 more source

Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy:the SEQUOIA-HCM trial [PDF]

BACKGROUND AND AIMS: The role of biomarker testing in the management of obstructive hypertrophic cardiomyopathy (oHCM) is not well defined. This pre-specified analysis of SEQUOIA-HCM (NCT05186818) sought to define the associations between clinical ...
Hegde, Sheila, Januzzi, James, Abraham, Theodore, Watkins, Hugh, Heitner, Stephen, Solomon, Scott, Jacoby, Daniel L., Malik, Fady I., Kulac, Ian, Solomon, Scott D., Coats, Caroline, Maron, Martin, Heitner, Stephen B., Hagege, Albert, Wohltman, Amy, Coats, Caroline J., Lee, Matthew M. Y., Masri, Ahmad, Meng, Lisa, Abraham, Theodore P., Kulac, Ian J., Tfelt-Hansen, Jacob, Claggett, Brian, Maron, Martin S., Kupfer, Stuart, Januzzi, James L., Barriales-Villa, Roberto, Brinkley, Douglas, Jacoby, Daniel, Marshall Brinkley, Douglas, Malik, Fady, Claggett, Brian L., Hegde, Sheila M., Owens, Anjali T., SEQUOIA-HCM Investigators, Owens, Anjali, Ho, Carolyn Y., Ho, Carolyn, Lee, Matthew, Olivotto, Iacopo, Lee, Matthew M Y, Ho, Carolyn Y, Claggett, Brian L, Maron, Martin S, Malik, Fady I, Kulac, Ian J, Owens, Anjali T, Hegde, Sheila M, Solomon, Scott D, Jacoby, Daniel L, Heitner, Stephen B, Januzzi, James L, Abraham, Theodore P, Brinkley, Douglas Marshall, Coats, Caroline J   +54 more
core   +2 more sources

Efficacy and Safety of Percutaneous Transluminal Septal Myocardial Ablation Treating Hypertrophic Cardiomyopathy: Systematic Review and Meta‐Analysis

International Journal of Clinical Practice, Volume 2025, Issue 1, 2025.
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is one of the invasive therapeutic measures for the treatment of patients with obstructive hypertrophic cardiomyopathy (HCM). Objective: To systematically evaluate the efficacy and safety of PTSMA in patients with HCM.
Sun Qinyu, Deng Yifan, Yu Jiling, Zhang Zhaoyuan, Cao Gan, Yang Tianxiao, Fang Zhen, Ji Jun, He Shenghu, Zhang Jing, Luigi Sciarra   +10 more
wiley   +1 more source

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +1 more source

Magnetic resonance imaging evaluation of the effects of myosin inhibitors (mavacamten and aficamten) in hypertrophic cardiomyopathy: a systematic review and case report

Monaldi Archives for Chest Disease
Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder, affecting approximately 1 in 250 individuals. It is defined by unexplained left ventricular (LV) hypertrophy in the absence of other identifiable cardiac or systemic causes.
Carolina Bernardes, João Gomes Carvalho, Patrícia Rodrigues, Manuela França   +3 more
doaj   +1 more source

Cardiomyopathy: pathogenesis and therapeutic interventions

MedComm, Volume 5, Issue 11, November 2024.
Cardiomyopathy is a group of diseases characterized by structural and functional damage to the myocardium. Many specific gene mutations, environmental factors, and metabolic disorders may cause cardiomyopathy. Traditional therapeutic includes drug and surgery. With the growing comprehension of the molecular mechanisms underlying cardiomyopathy.
Shitong Huang, Jiaxin Li, Qiuying Li, Qiuyu Wang, Xianwu Zhou, Jimei Chen, Xuanhui Chen, Abdelouahab Bellou, Jian Zhuang, Liming Lei   +9 more
wiley   +1 more source

Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy Management in a Large Single Center Cohort

Reviews in Cardiovascular Medicine
Background: Cardiac myosin inhibitors (CMIs), including Mavacamten and Aficamten, have emerged as a groundbreaking treatment for hypertrophic cardiomyopathy (HCM).
Ali Amr, Elham Kayvanpour, Christoph Reich, Jan Koelemen, Shamily Asokan, Norbert Frey, Benjamin Meder, Farbod Sedaghat-Hamedani   +7 more
doaj   +1 more source

From amoeboid myosin to unique targeted medicines for a genetic cardiac disease

Frontiers in Physiology
The importance of fundamental basic research in the quest for much needed clinical treatments is a story that constantly must be retold. Funding of basic science in the USA by the National Institutes of Health and other agencies is provided under the ...
James A. Spudich
doaj   +1 more source